MASLD – Prävention und ernährungsmedizinische Behandlungsmöglichkeiten

Zusammenfassung

Diese Übersicht nutzt die neue Nomenklatur der Fettlebererkrankungen, die im Juni 2023 von der amerikanischen Lebergesellschaft AASLD und der europäischen Lebergesellschaft EASL in einem umfangreichen Konsensusverfahren etabliert wurde. Die Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) unterstützt die neue Namensgebung mit Nachdruck.

Körperliche Inaktivität, zunehmendes Körpergewicht und höheres Lebensalter haben in den letzten Jahrzehnten zu einem Anstieg der Prävalenz der metabolischen Dysfunktion assoziierten Fettlebererkrankung (MASLD) geführt. In vielen Industrieländern ist die MASLD inzwischen die häufigste chronische Lebererkrankung. MASLD ist eine Form der steatotischen Lebererkrankung, die eng mit Stoffwechselkrankheiten wie Typ-2-Diabetes, Dyslipidämie und Adipositas verbunden ist. Sie wird daher auch als metabolisch assoziierte Fettleber bezeichnet [1].

Abstract

This review uses the new nomenclature of fatty liver diseases established in June 2023 by the American liver society AASLD and the European liver society EASL in a comprehensive consensus process. The German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) strongly supports the new naming.

Physical inactivity, increasing body weight and older age have caused an increase in the prevalence of metabolic dysfunction associated fatty liver disease (MASLD) in recent decades. In many industrialized countries MASLD is now the most common chronic liver disease. MASLD represents a form of steatotic liver disease closely associated with metabolic diseases such as type 2 diabetes, dyslipidemia, and obesity. It is therefore also referred to as metabolically associated fatty liver.

Schlüsselwörter

Fettleber - MASLD - mediterrane Ernährung - Insulinresistenz

Key words

fatty liver - MASLD - mediterranean diet - insulin resistance

Publication History

Article published online:
20 October 2023

• Literatur

• 1 Roeb E. Excess body weight and metabolic (dysfunction)-associated fatty liver disease (MAFLD). Visceral Medicine 2021; 37: 373-280
• 2 Roeb E, Canbay A, Bantel H. et al. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021-025. Z Gastroenterol 2022; 60: 1346-1421
• 3 Gerber L, Otgonsuren M, Mishra A. et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther 2012; 36: 772-781
• 4 Stewart KE, Haller DL, Sargeant C. et al. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int 2015; 35: 936-943
• 5 Yu C, Gao J, Ge X. et al. Healthy lifestyle is associated with reduced mortality in patients with non-alcoholic fatty liver disease. Nutrients 2022; 14: 3785
• 6 Plauth M, Bernal W, Dasarathy S. et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019; 38: 485-521
• 7 Garvey WT, Mechanick JI, Brett EM. et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016; 22: 1-203
• 8 Wirth A, Wabitsch M, Hauner H. The prevention and treatment of obesity. Dtsch Arztebl Int 2014; 111: 705-713
• 9 Younossi ZM, Corey KE, Lim JK. AGA Clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. Gastroenterology 2021; 160: 912-918
• 10 Hickman IJ, Jonsson JR, Prins JB. et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-419
• 11 Thomas EL, Brynes AE, Hamilton G. et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5813-5819
• 12 Harrison SA, Fecht W, Brunt EM. et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-86
• 13 Promrat K, Kleiner DE, Niemeier HM. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129
• 14 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367-378.e5 quiz e14-15
• 15 Berzigotti A, Albillos A, Villanueva C. et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology 2017; 65: 1293-1305
• 16 Larson-Meyer DE, Newcomer BR, Heilbronn LK. et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 2008; 16: 1355-1362
• 17 Johnson NA, Sachinwalla T, Walton DW. et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112
• 18 Hallsworth K, Fattakhova G, Hollingsworth KG. et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-1283
• 19 Sullivan S, Kirk EP, Mittendorfer B. et al. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012; 55: 1738-1745
• 20 Houghton D, Thoma C, Hallsworth K. et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol 2017; 15: 96-102.e3
• 21 Haufe S, Engeli S, Kast P. et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011; 53: 1504-1514
• 22 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
• 23 Baldry EL, Aithal GP, Kaye P. et al. Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: Results of a randomized controlled trial using 2 dietary approaches. Diabetes Obes Metab 2017; 19: 1179-1183
• 24 Deibert P, Lazaro A, Schaffner D. et al. Comprehensive lifestyle intervention vs soy protein-based meal regimen in non-alcoholic steatohepatitis. World J Gastroenterol 2019; 25: 1116-1131
• 25 Hohenester S, Christiansen S, Nagel J. et al. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol 2018; 315: G329-G338
• 26 Charidemou E, Ashmore T, Li X. et al. A randomized 3-way crossover study indicates that high-protein feeding induces de novo lipogenesis in healthy humans. JCI Insight 2019; 4: e124819
• 27 Markova M, Pivovarova O, Hornemann S. et al. Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes. Gastroenterology 2017; 152: 571-585.e578
• 28 Bray GA, Nielsen SJ, Popkin BM. Consumption of highfructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004; 79: 537-543
• 29 Roeb E, Weiskirchen R. Fructose and non-alcoholic steatohepatitis. Front Pharmacol 2021; 12: 634344
• 30 Stanhope KL, Schwarz JM, Keim NL. et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322-1334
• 31 Jensen T, Abdelmalek MF, Sullivan S. et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol 2018; 68: 1063-1075
• 32 Chung M, Ma J, Patel K. et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and metaanalysis. Am J Clin Nutr 2014; 100: 833-849
• 33 Chiu S, Sievenpiper JL, de Souza RJ. et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 2014; 68: 416-423
• 34 Stricker S, Rudloff S, Geier A. et al. Fructosekonsum – freie Zucker und ihr Einfluss auf die Gesundheit. Dtsch Arztebl Int 2021; 118: 71-80
• 35 Johnston RD, Stephenson MC, Crossland H. et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 2013; 145: 1016-1025.e1012
• 36 Shai I, Schwarzfuchs D, Henkin Y. et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359: 229-241
• 37 Pérez-Guisado J, Muñoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. J Med Food 2011; 14: 677-680
• 38 Ryan MC, Itsiopoulos C, Thodis T. et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59: 138-143
• 39 Trovato FM, Catalano D, Martines GF. et al. Mediterranean diet and non-alcoholic fatty liver disease: the need of extended and comprehensive interventions. Clin Nutr 2015; 34: 86-88
• 40 Misciagna G, Del Pilar Díaz M, Caramia DV. et al. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging 2017; 21: 404-412
• 41 Gelli C, Tarocchi M, Abenavoli L. et al. Effect of a counselingsupported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23: 3150-3162
• 42 Katsagoni CN, Papatheodoridis GV, Ioannidou P. et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr 2018; 120: 164-175
• 43 Tzima N, Pitsavos C, Panagiotakos DB. et al. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome; the ATTICA study. Nutr Metab (Lond) 2009; 6: 30
• 44 Kontogianni MD, Tileli N, Margariti A. et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr 2014; 33: 678-683
• 45 Aller R, Izaola O, de la Fuente B. et al. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutr Hosp 2015; 32: 2518-2524
• 46 Trovato FM, Martines GF, Brischetto D. et al. Fatty liver disease and lifestyle in youngsters: diet, food intake frequency, exercise, sleep shortage and fashion. Liver Int 2016; 36: 427-433
• 47 EASL-Guideline EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
• 48 Abenavoli L, Milic N, Peta V. et al. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 2014; 20: 16831-16840
• 49 Suárez M, Boqué N, Del Bas JM. et al. Mediterranean diet and multi-ingredient-based interventions for the management of non-alcoholic fatty liver disease. Nutrients 2017; 9: 1052
• 50 Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67: 829-846
• 51 Ma J, Hennein R, Liu C. et al. Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease. Gastroenterology 2018; 155: 107-117
• 52 Velasco N, Contreras A, Grassi B. The Mediterranean diet, hepatic steatosis and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2014; 17: 453-457
• 53 Gepner Y, Shelef I, Schwarzfuchs D. et al. Effect of distinct lifestyle interventions on mobilization of fat storage pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. Circulation 2018; 137: 1143-1157
• 54 Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment?. Lancet Diabetes Endocrinol 2018; 6: 249-258
• 55 Štefan L, Čule M, Milinović I. et al. The relationship between lifestyle factors and body composition in young adults. Int J Environ Res Public Health 2017; 14: 893
• 56 Wong VW, Wong GL, Chan RS. et al. Beneficial effects of lifestyle intervention in non-obese patients with nonalcoholic fatty liver disease. J Hepatol 2018; 69: 1349-1356
• 57 Buzzetti E, Linden A, Best LM. et al. Lifestyle modifications for nonalcohol-related fatty liver disease: a network metaanalysis. Cochrane Database Syst Rev 2021; 6: CD013156
• 58 Yaskolka Meir A, Rinott E, Tsaban G. et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut 2021; 70: 2085-2095
• 59 Mascaró CM, Bouzas C, Montemayor S. et al. Association between stages of hepatic steatosis and physical activity performance in adults with metabolic syndrome: A crosssectional analysis in FLIPAN Study. Nutrients 2022; 14: 1790